T-00127_HEV1
目录号 : GC32199T-00127_HEV1是一个phosphatidylinositol4-kinaseIIIbeta(PI4KB)抑制剂,其IC50值为60nM。
Cas No.:900874-91-1
Sample solution is provided at 25 µL, 10mM.
T-00127_HEV1 is a phosphatidylinositol 4-kinase III beta (PI4KB) inhibitor with an IC50 of 60 nM.
T-00127_HEV1 shows more potent anti-poliovirus (PV) activity (EC50 of 0.77 μM) than other candidate compounds (EC50 of 1.7 to 4.7 μM). GW5074 and T-00127_HEV1 almost completely inhibit PI4KB kinase activity at 10 μM (3% and 5% of residual activity, respectively), in contrast to AN-12-H5 (108% of activity [no inhibition])[1].
[1]. Arita M, et al. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J Virol. 2011 Mar;85(5):2364-72.
Kinase experiment: |
The inhibitory effect of T-00127_HEV1 at a concentration of 10 μM on in vitro cellular protein kinase activities is assessed by kinase profiling with an ATP concentration near the Km for each kinase. Inhibitory effects of GW5074, AN-12-H5, and T-00127_HEV1 at a concentration of 10 μM on in vitro PI kinase activities are assessed by the SelectScreen kinase profiling service with an ATP concentration of 10 μM. For T-00127_HEV1, the 50% inhibitory concentration (IC50) for in vitro PI4KB activity is also measured with an ATP concentration of 10 μM[1]. |
Cell experiment: |
RD cells (1.0×104 cells per well in 100 μL medium) in a 96-well plate are infected with PV1, EV71, or CVB3 at multiplicities of infection (MOI) of 10, 1.0, and 0.1 at 37°C for 1 h in the absence of T-00127_HEV1. The cells are washed three times with 10% FCS-DMEM, followed by the addition of 100 μL of 10% FCS-DMEM containing 10 or 0 μM T-00127_HEV1. Cells are collected at 16 h p.i., and then viral RNA is extracted from the cells using a viral RNA purification kit. The number of copies of the viral genome is quantified using a real-time PCR system[1]. |
References: [1]. Arita M, et al. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J Virol. 2011 Mar;85(5):2364-72. |
Cas No. | 900874-91-1 | SDF | |
Canonical SMILES | CC1=NC2=C(C3=CC=C(OC)C(OC)=C3)C(C)=NN2C(NCCN4CCOCC4)=C1 | ||
分子式 | C22H29N5O3 | 分子量 | 411.5 |
溶解度 | DMSO : 50 mg/mL (121.51 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.4301 mL | 12.1507 mL | 24.3013 mL |
5 mM | 0.486 mL | 2.4301 mL | 4.8603 mL |
10 mM | 0.243 mL | 1.2151 mL | 2.4301 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet